STOCK TITAN
  1. Home
  2. News
  3. URGN

UroGen Pharma Ltd - URGN STOCK NEWS

Welcome to our dedicated news page for UroGen Pharma (Ticker: URGN), a resource for investors and traders seeking the latest updates and insights on UroGen Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect UroGen Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of UroGen Pharma's position in the market.

News
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
Rhea-AI Summary
UroGen Pharma Ltd. (Nasdaq: URGN) will report second quarter 2023 financial results on Thursday, August 10, 2023, followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
conferences earnings
-
News
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.2%
Tags
none
-
News
UroGen Announces $120 Million Private Placement of Ordinary Shares
Rhea-AI Summary
UroGen Pharma Ltd. (URGN) announces a definitive securities purchase agreement for a private placement, led by RA Capital Management L.P. and Great Point Partners LLC, with gross proceeds of approximately $120 million. The company intends to use the net proceeds for non-clinical and clinical development activities, commercialization expenses, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
98.56%
Tags
none
News
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
Rhea-AI Summary
UroGen Pharma announces positive topline data from Phase 3 trials of UGN-102 for bladder cancer treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
98.56%
Tags
clinical trial
-
News
UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
Rhea-AI Summary
UroGen Pharma appoints James Robinson, former President and CEO of Urovant Sciences, to its Board of Directors. Robinson's experience in the biopharmaceutical industry will provide valuable guidance as the company expands access to JELMYTO and advances its lead clinical development program. Robinson has over 30 years of experience and has excelled in building and leading organizations. He served on the Urovant board of directors and has held prominent roles at Paragon Biosciences, Alkermes PLC, Astellas U.S., and Schering-Plough Pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
management
-
News
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
none
News
UroGen Pharma to Host UGN-102 Data Event on July 27, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
conferences
-
News
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
none
-
News
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none
News
UroGen Pharma to Present at Upcoming Investor Conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
Stock URGN logo
UroGen Pharma Ltd

Nasdaq:URGN

URGN Rankings

#3010 Ranked by Market Cap
#2431 Ranked by Stock Gains
N/A Ranked by Dividends

URGN Stock Data

515.24M
24.37M
11.35%
70.5%
12.27%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
9 Hataasiya St

About URGN

urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.